Literature DB >> 22546749

Expected net present value of sample information: from burden to investment.

Peter S Hall1,2,3, Richard Edlin1, Samer Kharroubi4, Walter Gregory2, Christopher McCabe1.   

Abstract

The Expected Value of Information Framework has been proposed as a method for identifying when health care technologies should be immediately reimbursed and when any reimbursement should be withheld while awaiting more evidence. This framework assesses the value of obtaining additional evidence to inform a current reimbursement decision. This represents the burden of not having the additional evidence at the time of the decision. However, when deciding whether to reimburse now or await more evidence, decision makers need to know the value of investing in more research to inform a future decision. Assessing this value requires consideration of research costs, research time, and what happens to patients while the research is undertaken and after completion. The investigators describe a development of the calculation of the expected value of sample information that assesses the value of investing in further research, including an only-in-research strategy and an only-with-research strategy.

Entities:  

Mesh:

Year:  2012        PMID: 22546749     DOI: 10.1177/0272989X12443010

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  6 in total

1.  Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study.

Authors:  Joshua A Roth; Ruth Etzioni; Teresa M Waters; Mary Pettinger; Jacques E Rossouw; Garnet L Anderson; Rowan T Chlebowski; Joann E Manson; Mark Hlatky; Karen C Johnson; Scott D Ramsey
Journal:  Ann Intern Med       Date:  2014-05-06       Impact factor: 25.391

2.  Value-engineered translation for regenerative medicine: meeting the needs of health systems.

Authors:  Tania Bubela; Christopher McCabe
Journal:  Stem Cells Dev       Date:  2013-12       Impact factor: 3.272

3.  Cost-Utility Analysis of Prophylactic Dextrose Gel vs Standard Care for Neonatal Hypoglycemia in At-Risk Infants.

Authors:  Matthew J Glasgow; Richard Edlin; Jane E Harding
Journal:  J Pediatr       Date:  2020-07-04       Impact factor: 4.406

4.  Navigating time and uncertainty in health technology appraisal: would a map help?

Authors:  Christopher McCabe; Richard Edlin; Peter Hall
Journal:  Pharmacoeconomics       Date:  2013-09       Impact factor: 4.981

5.  Acceptance and commitment therapy for adults with advanced cancer (CanACT): study protocol for a feasibility randomised controlled trial.

Authors:  Joseph Low; Marc Serfaty; Sarah Davis; Victoria Vickerstaff; Anna Gola; Rumana Z Omar; Michael King; Adrian Tookman; Janet St John Austen; Karen Turner; Louise Jones
Journal:  Trials       Date:  2016-02-11       Impact factor: 2.279

6.  Population-level intervention and information collection in dynamic healthcare policy.

Authors:  Lauren E Cipriano; Thomas A Weber
Journal:  Health Care Manag Sci       Date:  2017-09-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.